Jouve, Jean-Louis <br/><br/>
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.  [electronic resource] 

 -  Journal of hepatology  09 2019 
 - 516-522 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1600-0641 
<br/><br/><label>Standard No.: </label>10.1016/j.jhep.2019.04.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carcinoma, Hepatocellular--drug therapy<br/>Diarrhea--chemically induced<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Kaplan-Meier Estimate<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Pravastatin--adverse effects<br/>Prognosis<br/>Progression-Free Survival<br/>Quality of Life<br/>Sorafenib--adverse effects